Complete calendar at IPOpremium.com
(1) Based in Durham, NC, Scynexis ($SCYX) scheduled a $55 million IPO on the Nasdaq for the week of April 21,2014.
Now the number of shares is 7.3 million shares at a range of $7-8, with a $141 million market capilization. Earlier it was 4.2 million shares at $12-14, also to raise $55 million, but with a $204 million market capitalization.
SCYX is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs.
(2) Based in Midlothian, United Kingdom, Quotient ($QTNT) originally scheduled a $75 million IPO on the Nasdaq with a market capitalization of $216 million at a price range midpoint of $15 for Wednesday, April 16, 2014.
The price range has been lowered to $9-$11 to raise $50 million at a market capitalization of $141 million.
QTNT is an established, commercial-stage diagnostics company committed to reducing healthcare costs and improving patient care through the development and commercialization of innovative tests for blood grouping and serological disease screening, commonly referred to as transfusion diagnostics.
(3) Based in Burlington, MA, Aldeyra Therapeutics ($ALDX) originally scheduled a $25 million IPO on the Nasdaq with a market capitalization of $69 million at a price range midpoint of $11 for Friday, April 11, 2014.
ALDX has been rescheduled for Friday, April 25, 2014.
ALDX is a biotechnology company focused primarily on the development of products to treat immune-mediated, inflammatory, orphan, and other diseases that are thought to be related to a naturally occurring toxic chemical species known as free aldehydes.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer